Cooperative Agreement U01CA296432
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$720K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Massachusetts, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $1,332,996 Cooperative Agreement (U01) grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Cold Spring Harbor Laboratory (CSHL) to develop computational tools for accurately inferring genetic ancestry from cancer-derived molecular data. The project aims to enable large-scale analysis of cancer genomics data to study the relationship between cancer biology and patient genetic ancestry, without requiring the patient's...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $942,442 in funding to the Dana-Farber Cancer Institute, Inc. over the period of September 1, 2024 to August 31, 2031. The goal of this research is to identify the mechanisms driving rapid evolution of cancer genomes, particularly through processes like chromothripsis and chromoplexy. The project will leverage single-cell genomics methods developed by the...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
This $416,745 Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to develop an Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics. The key products and services to be delivered under this 3-year project include:
Creation of a Regulatory-Element-Target-Gene Atlas to enable researchers to explore connections between regulatory elements and cancer-associated...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $872,555 to the Dana-Farber Cancer Institute to enhance and further develop informatics methods for long-read cancer genome sequencing. The project aims to catalyze long-read cancer genomics by improving bioinformatic tools for detecting and characterizing somatic genetic alterations from long-read sequencing data. This will be achieved through three main activities: 1)...
The National Cancer Institute (NCI) awarded a $432,304 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The Trustees of Columbia University in the City of New York, Health Sciences Division, to develop enhanced cancer risk prediction models for underrepresented Black and Hispanic populations. The 5-year project, beginning January 3, 2025, aims to create novel data integration methods that effectively leverage diverse data sources, including electronic...
The National Cancer Institute (NCI) has awarded a $686,993 Cooperative Agreement under the Cancer Cause and Prevention Research Program (CFDA 93.393) to The Trustees of Columbia University in the City of New York to implement electronic health record (EHR)-based strategies and decision support for hereditary breast and ovarian cancer (HBOC) genetic testing among multiethnic women. The project aims to address the significant underutilization of HBOC genetic testing, particularly among women of...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will provide $2,136,715.00 over 4 years, starting on August 1, 2024, to conduct research aimed at "Harnessing DNA Methylation in Peripheral Blood for Improved Colorectal Cancer Prevention."
The primary grantee, Harvard T.H. Chan School of Public Health, will lead the research which will involve collaborations with sub-awardees Dana-Farber Cancer Institute and Boston...
The National Cancer Institute (NCI) awarded a $766,773 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Dana-Farber Cancer Institute, Inc. (DFCI) for the project "Inclusion of Diverse and Medically Underserved Populations in the Design and Implementation of the PREMMPLUS Patient-Facing App." The grant aims to evaluate a patient-facing mobile app version of the PREMMPLUS multigene cancer risk assessment model in diverse community health...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $635,033 to The Johns Hopkins University to advance research on the genetic basis of a cancer-prone syndrome caused by long telomere length. The research aims to identify additional novel mechanisms underlying this syndrome, define the role of genetic variants in familial cancer predisposition, and examine how long telomere length influences cancer genomic profiles. This...